LITTLETON, Mass.--(BUSINESS WIRE)--At the first virtual meeting of the American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting, October 23rd to the 29th, Mevion will highlight its research and development progress demonstrating the FLASH effect on commercially available MEVION S250i compact proton accelerators.
FLASH Therapy*, a non-invasive, ultra-high dose rate delivered at incredible speeds, may dramatically improve the cancer-fighting benefits of therapeutic radiation by shortening treatment courses and lessening side effects. Driven by innovation and guided by a coalition of clinical partners and FLASH thought leaders, Mevion’s Advanced Development team has yielded strong results from an initial small animal study that could propel this potentially promising cancer treatment forward.
“The initial results from our study conducted this summer on a commercial production accelerator produced very promising results and a FLASH effect at the Bragg Peak,” said Townsend Zwart, Ph.D. vice president, Advanced Development at Mevion. “Our MEVION S250i accelerator is a powerful and robust system, inherently capable of delivering the ultra-high dose rates at ultra-high speeds needed for FLASH on a platform that will make it easier and simpler for centers to study the potentially revolutionary effects of FLASH Therapy without modifications to the accelerator or shielding.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
MEVION S250i accelerators have a particularly high intra-pulse dose rate. A high intra-pulse dose rate has been associated, in previous clinical experience, as a key to a consistent FLASH effect. The study and its results will be presented during the annual meeting on Tuesday, October 27, at 11:45 AM in the Innovation Hub.
Image-Guided Positioning Suite
A range of natively integrated imaging and patient positioning options are now available on Mevion systems. While other proton manufacturers provide a locked-in solution built into their system, Mevion proton systems are designed with a unique open architecture to keep centers imaging and positioning solutions current with the future advancements and evolution in IGPT. Customizable solutions from best-in-class providers such as medPhoton, Siemens®, and Stryker Spine for 3D imaging, C-Rad™, and DYN’R® provide surface tracking and motion management, and CIVCO Radiotherapy, Orfit®, and Qfix™ enable precise patient positioning and immobilization, allowing centers to configure the best solution to meet their needs.